Three-year trial data show "outstanding" safety of Endeavor DES
This article was originally published in Clinica
Executive Summary
Endeavor, Medtronic's zotarolimus-eluting stent, has "significant safety advantages" over Boston Scientific's paclitaxel-coated rival Taxus device, researchers say.